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Potent combination antiretroviral therapy that was
introduced in the mid-1990s for treatment of HIV-1
infection has resulted in unprecedented decreases in
HIV-1 replication and increases in CD4+ T cell
counts in many individuals. Coincident with the
introduction of potent combination antiretroviral
therapy, substantial declines in AIDS-related mor-
bidity and mortality have been observed. Although
these declines strongly suggest that signi®cant
immune reconstitution is occurring, increasing evi-
dence suggests that immune reconstitution is neither
uniform nor complete in all treated individuals.
Clinical data suggest that some HIV-1-associated
malignancies have not declined despite the new
therapies, and that not all treated individuals recon-
stitute CD4+ T cell numbers to normal values.
Laboratory studies reveal that immune responses to
ubiquitous antigens are reconstituted, but that
responses to rarely encountered antigens, such as
tetanus, are not reconstituted without repeat vaccin-
ation. Many questions remain concerning the extent
and clinical signi®cance of the immune reconstitu-
tion that occurs in the setting of antiretroviral drug
therapy. A better understanding of the nature of the
immune reconstitution that results from potent anti-
retroviral therapy is critical to the optimal clinical
management of HIV-1-infected individuals, and may
provide important insights into the immunopatho-
genesis of HIV-1 infection as well. Key words: anti-
retroviral therapy/CD4+ T lymphocytes/HIV-1/immune
reconstitution. Journal of Investigative Dermatology
Symposium Proceedings 6:212±218, 2001
I
nfection with the human immunode®ciency virus type 1
(HIV-1) results in the progressive loss of CD4+ T
lymphocytes and a variety of immune functions. In the
absence of therapy, most infected individuals eventually
develop opportunistic infections (OI) and ultimately die
prematurely. The introduction of potent antiretroviral therapy
for HIV-1 infection in the past 5 y has led to dramatic
increases in CD4+ T cell numbers, decreases in OI, and
improvements in survival, suggesting that immune reconstitution
is occurring in treated individuals; however, the nature and
extent of this immune reconstitution is not fully understood. A
better understanding of the immune reconstitution that occurs
in the setting of potent antiretroviral therapy is critical to the
optimal treatment of HIV-1-infected individuals.
IMPACT OF POTENT ANTIRETROVIRAL THERAPY
ON AIDS-RELATED MORBIDITY AND MORTALITY
Prior to the mid-1990s, the standard of care for treatment of
HIV-1 infection consisted of monotherapy and dual therapy
with HIV-1 nucleoside analog reverse transcriptase inhibitors.
These therapies were shown to produce modest increases in
CD4+ T cell counts and some improvements in survival (Delta
Coordinating Committee, 1996; Hammer et al, 1996;
Katzenstein et al, 1996; Marschner et al, 1998). With the
introduction of protease inhibitors in the mid-1990s and their
use in combination with other antiviral drugs, much more
profound and sustained viral suppression and larger increases in
CD4+ T cell counts were observed than ever before. The ®rst
widely used potent combination antiretroviral therapies for
HIV-1 infection consisted of an HIV-1 protease inhibitor and
two nucleoside analog reverse transcriptase inhibitors (Collier
et al, 1996; Gulick et al, 1997; Hammer et al, 1997). Over the
past 5 y, a variety of combinations of antiviral drugs have been
shown to be equally if not more potent in suppressing HIV-1
replication (D'Aquila et al, 1996; Murphy et al, 1999; Staszewski
et al, 1999; Gulick et al, 2001). These various combinations of
potent antiviral medications, frequently referred to as highly
active antiretroviral therapy (HAART), have become the
standard of care for HIV-1 infection (Carpenter et al, 2000).
Commensurate with the introduction of HAART, there has
been a dramatic decline in mortality and morbidity from HIV-1
disease in the U.S.A. and other industrialized countries. In the
U.S.A., AIDS-related deaths in adults have steadily declined
from a peak of 50,610 in 1995 to 16,273 in 1999 (Centers for
Disease Control and Prevention, 1999a). Profound decreases in
the incidence of many OI, such as Pneumocystis carinii
pneumonia (PCP), Mycobacterium avium complex (MAC), and
cytomegalovirus (CMV) retinitis, have been reported over the
same period of time (Brodt et al, 1997; Egger et al, 1997;
Correll et al, 1998; Hogg et al, 1998; Holtzer et al, 1998;
Mocroft et al, 1998; Palella et al, 1998; Jones et al, 1999a; Paul
et al, 1999; Pezzotti et al, 1999; Kaplan et al, 2000). These
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declines in OI cannot be explained by increases in prophylactic
measures to prevent them (Palella et al, 1998; Jones et al,
1999a). Randomized trials of potent combination antiretroviral
therapy compared with less potent regimens have demonstrated
that it is the superior control of HIV-1 replication and the
increase in CD4+ T lymphocyte counts induced by potent
regimens that are associated with the reduced incidence of OI
(Cameron et al, 1997; Hammer et al, 1997; Hirsch et al, 1999).
Further evidence to suggest that HAART results in immune
reconstitution comes from numerous case reports of the
resolution of OI after initiation of therapy. Progressive multi-
focal leukoencephalopathy (PML) (Baldeweg and Catalan, 1997;
Baqi et al, 1997; Domingo et al, 1997; Elliot et al, 1997; Power
et al, 1997; Albrecht et al, 1998; Cinque et al, 1998), diarrhea
due to cryptosporidia and microsporidia (Goguel et al, 1997;
Carr et al, 1998), treatment-refractory oral candidiasis (Zingman,
1996; Valdez et al, 1998), molluscum contagiosum (Hicks et al,
1997; Hurni et al, 1997), and Kaposi's sarcoma (Conant et al,
1997; Murphy et al, 1997; Parra et al, 1998) have been reported
to regress after the initiation of potent combination antiretro-
viral therapy. Individuals with a history of CMV retinitis, which
in the absence of CMV-speci®c therapy usually progresses
within a few weeks, have had primary anti-CMV therapy
withdrawn without disease recurrence after receiving HAART
(Uthayakumar et al, 1997; Jabs et al, 1998). Similarly, dissem-
inated MAC infection, which previously required lifelong
therapy for containment, has failed to recur in individuals
despite cessation of primary therapy after a good response to
HAART (Aberg et al, 1998). Prophylactic PCP therapy has
been safely withdrawn in subjects previously at risk for PCP
due to a low CD4+ T cell count after they had achieved
sustained increases in CD4+ T cell counts (Furrer et al, 1999;
Schneider et al, 1999; Weverling et al, 1999).1 These data
suggest that the decrease in OI seen with potent antiretroviral
therapy is due not only to a halt in the progression of HIV-1-
induced immune de®ciency, but also to reconstituted immunity
that allows individuals to contain infections immunologically
that previously they were unable to control. As a result of these
data, of®cial recommendations regarding prophylaxis of OI have
been modi®ed to allow for the discontinuation of primary PCP
and MAC prophylaxis in individuals with sustained elevations in
CD4+ T cell counts above threshold levels in the setting of
HAART (Centers for Disease Control and Prevention, 1999b).
Further clinical evidence that HAART results in immune
reconstitution comes from an increasing number of observations
of immune in¯ammatory syndromes in the setting of initiation
of HAART. These syndromes, which consist of severe and
sometimes unusual clinical manifestations of OI shortly after the
introduction of HAART, are believed to be due to reconsti-
tution of immunity to pre-existing, but clinically occult OI.
Severe CMV retinitis, including the more unusual presentation
of vitritis associated with retinitis, has been reported to occur in
patients recently initiated on HAART (Gilquin et al, 1997;
Jacobson et al, 1997). PML, including one atypical case in
which contrast enhancing lesions developed 2 mo after presen-
tation (Kotecha et al, 1998; Mayo et al, 1998), has also been
observed to develop shortly after initiation of HAART. Focal
lymphadenitis and other unusual clinical manifestations of MAC,
other atypical mycobacteria, and Mycobacterium tuberculosis (MTB)
(Chien and Johnson, 1998; Race et al, 1998; Foudraine et al,
1999), have been reported in individuals who had recently
started HAART. Similar immunopathology has been suggested
as the cause for elevations in liver function tests in patients with
chronic hepatitis B or C infection following initiation of
HAART (Carr et al, 1997; Vento et al, 1998). An association
has been described between initiation of HAART and serious
and sometimes fatal cases of Castleman's disease, which is
believed to be caused by human herpesvirus-8 (HHV-8)
infection (Zietz et al, 1999). Thus, the immune reconstitution
brought about by initiation of potent antiretroviral therapy can
in some instances be paradoxically deleterious to treated
individuals. In general, with the continuation of HAART
and, in some instances, treatment with steroids, these immune
in¯ammatory syndromes have resolved.
Although many lines of evidence suggest that substantial
immune reconstitution occurs in individuals treated with
HAART, clinical data suggest that this immune reconstitution
is not necessarily uniform or complete in every treated
individual. Despite evidence that prophylaxis against CMV
and PCP can be safely discontinued when CD4+ T cell counts
rise above the traditional threshold values for prophylaxis,
several studies have reported the presentation of these and other
OI at higher CD4+ T cell counts than was usually seen in the
past (Law et al, 1999; Pezzotti et al, 1999). The CD4+ T cell
nadir has been shown to be a signi®cant risk factor for AIDS-
de®ning illnesses or death even after CD4+ T cell increases on
HAART have occurred (Ledergerber et al, 1999; Miller et al,
1999). A few case reports, such as recurrent CMV retinitis in
an individual treated with HAART for over 1 y and with a
CD4+ T cell count over 400 cells per mm3 (Johnson, 2001),
suggest that some individuals may have persistent immunologic
lacunae despite sustained increases in CD4+ T cell numbers.
Further evidence that immune reconstitution in the setting of
HAART may not be complete comes from the observation that
not all HIV-1-associated illnesses have been found to decline.
HIV-1-associated malignancies in particular have had quite
variable responses to HAART. Declines in the incidence of
Kaposi's sarcoma (Jacobson et al, 1999; Jones et al, 1999b;
Rabkin et al, 1999; Sparano et al, 1999), as well as primary
brain lymphoma (Jones et al, 1999b), have been reported since
the introduction of HAART; however, the incidence of other
HIV-1-associated malignancies, including immunoblastic lym-
phoma, invasive cervical cancer, Hodgkin's lymphoma, and
Burkitt's lymphoma, have not declined or have declined more
slowly than Kaposi's sarcoma over the same time interval
(Grulich, 1999; Jacobson et al, 1999; Jones et al, 1999b; Rabkin
et al, 1999). It may be that it takes longer for HAART to
reverse the oncogenic diathesis induced by HIV-1 infection
than the susceptibility to OI. Alternatively, or in addition, there
may be a persistent oncogenic risk induced by HIV-1 infection
that cannot be eliminated by the immune restoration induced
by HAART. Studies that examine the clinical outcomes of
individuals treated with HAART over the long term are needed
to assess more fully the immune reconstitution induced by
HAART.
NUMERICAL AND FUNCTIONAL CHANGES IN CD4+
T LYMPHOCYTES IN THE CONTEXT OF HAART
Progressive loss of CD4+ T cell numbers and functions is the
hallmark of HIV-1 infection. During the course of untreated
disease, CD4+ T cell counts drop from normal values, which
are usually over 800 cells per mm3, to less than 200 CD4+ T
cells per mm3, which in and of itself constitutes a diagnosis of
AIDS. Historically, CD4+ T cell counts have been used to
guide clinical decisions as to when to start antiretroviral therapy
or prophylaxis for OI because they are highly predictive of the
risk of OI and death (Dolan et al, 1995). In the setting of
HAART, dramatic increases in CD4+ T lymphocyte counts
have been observed. An average increase of 150 CD4+ cells per
mm3 in the ®rst year of therapy has been seen in individuals
with moderately advanced disease (Collier et al, 1996; Gulick
1Dworkin M, Hanson D, Jones J, et al: The risk for Pneumocystis carinii
pneumonia (PCP) and disseminated nontuberculous mycobacteriosis
(Dmb) after an antiretroviral therapy (ART) associated increase in the
CD4+ T lymphocyte count. In: Abstracts of the 6th Conference on Retroviruses
and Opportunistic Infections, Chicago, IL, January 31±February 4. Alexandria,
VA: Foundation for Retrovirology and Human Health, 1999 (abstr. 692)
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et al, 1997; Hammer et al, 1997; Connick et al, 2000). The
magnitude of CD4+ T cell increases has been shown to be
directly correlated with the magnitude of virus suppression,
although there is substantial variability among patients (Collier
et al, 1996; Gulick et al, 1997; Hammer et al, 1997; Connick
et al, 2000). A critical clinical question is whether CD4+ T cell
counts in individuals treated with HAART can be interpreted
in the same way as those in untreated individuals.
Peripheral blood CD4+ T cell increases in the setting of potent
antiretroviral therapy occur in two phases (Autran et al, 1997;
Pakker et al, 1997; Bisset et al, 1998; Giorgi et al, 1998; Gray et al,
1998; Li et al, 1998; Pakker et al, 1998; Connick et al 2000). The
®rst phase increase, which occurs over the ®rst 8 wk of therapy,
tends to be more precipitous than the second, and consists primarily
of CD4+ T cells with a memory phenotype. Several lines of
evidence suggest that the ®rst phase increase primarily re¯ects
redistribution of CD4+ T cells out of lymphoid tissues, perhaps
due to downregulation of adhesion molecules in these tissues
coincident with suppression of HIV-1 replication (Bucy et al,
1999). The T cell receptor (TCR) repertoires of the cells of the ®rst
phase increase are similar to the pre-existing repertoire, which is
often aberrant (Connors et al, 1997; Gorochov et al, 1998;
Lederman et al, 1998). The ®rst phase increase in CD4+ T
lymphocyte numbers observed in peripheral blood has not been
found in lymphoid tissues (Zhang et al, 1998); instead, very little or
no increase has been observed in lymphoid tissues during the ®rst 2
mo of HAART. As the vast majority of lymphocytes are found in
lymphoid tissues, the absence of increases in CD4+ T cells in
lymphoid tissues supports the theory that the ®rst phase primarily
represents redistribution of CD4+ T cells into the peripheral blood.
The second phase increase, which occurs after the ®rst 8 wk of
therapy, is usually slower than the ®rst (Autran et al, 1997; Pakker
et al, 1997; Bisset et al, 1998; Giorgi et al, 1998; Gray et al, 1998; Li
et al, 1998; Pakker et al, 1998; Connick et al, 2000), but similar in
tempo to what has been observed in cancer patients treated with
chemotherapy (Hakim et al, 1997). The second phase increase
consists primarily of CD4+ T cells with a naõÈve phenotype.
Phenotypically naõÈve cells are not necessarily newly synthesized, as
reversion of cells from a memory to a naõÈve phenotype has been
reported (Bell et al, 1990; Walker et al, 1998). Studies of lymphoid
tissues, however, have demonstrated CD4+ T cell increases during
the second phase of CD4+ T cell increases, suggesting that these
represent true increases in total body CD4+ T cells (Zhang et al,
1998). The TCR repertoires of the second phase increases have
been less extensively studied, but several studies suggest that they
may be trending towards a more normal repertoire than that prior
to HAART (Gorochov et al, 1998; Kostense et al, 1998), further
bolstering the theory that HAART results in new CD4+ T cell
synthesis. A novel method of identifying thymically derived cells
using T cell receptor excision circles (TREC) that are a byproduct
of TCR rearrangement in the thymus as a marker, has demon-
strated increases in TREC in the naõÈve pool of peripheral blood
cells in HIV-1-infected individuals following initiation of HAART
(Douek et al, 1998), suggesting that new CD4+ T cells are being
generated by the thymus. The number of phenotypically naõÈve cells
in HAART-treated individuals has been correlated with the
abundance of thymic tissue determined by CT scan, further
suggesting that the thymus may be an important source of newly
synthesized cells in patients on HAART (McCune et al, 2000). It
has been argued, however, that the increase in TREC-containing
cells observed in the setting of HAART may be the result of
diminished proliferation in the naõÈve CD4+ T cell pool and not
necessarily due to synthesis of naõÈve cells in the thymus (Hazenberg
et al, 2000). Thus, the origin of the second phase increases in
CD4+ T cells, whether from thymically or peripherally derived T
cells, remains unclear.
Increasing evidence suggests that there may be a third or plateau
phase when CD4+ T cell reconstitution stops. Although some
treated individuals achieve and maintain normal CD4+ T cell
counts, many others, particularly those with moderately advanced
HIV-1 infection, do not fully reconstitute their CD4+ T cells to
normal numbers (Notermans et al, 1999).2 The determinants of the
long-term ability to reconstitute CD4+ T cell numbers have not
been de®ned. Whether this could represent an HIV-1-induced
defect in the generation of CD34+ bone marrow precursors or in
thymic regeneration is unclear. The clinical consequences of
incomplete CD4+ T cell regeneration are also unknown. The
failure to reconstitute any CD4+ T cells has been shown to be
associated with a worse outcome among individuals with moder-
ately advanced HIV-1 infection (Grabar et al, 2000), but it is
unknown what the implications of partial CD4+ T cell reconsti-
tution are.
In addition to increases in CD4+ T cell numbers, several
studies have demonstrated improved CD4+ T cell function in
individuals treated with HAART. The sequential loss of T
lymphocyte proliferative responses to antigens, alloantigens, and
mitogens, as well as delayed type hypersensitivity skin test
responses, are well described in HIV-1 infection, and have been
found to be prognostic of disease progression (Clerici et al,
1989; Blatt et al, 1993; Dolan et al, 1995). The recovery of T
lymphocyte proliferative responses to antigens such as CMV,
MAC, Candida, and MTB, and DTH responses to Candida
following initiation of HAART, has been reported by several
groups (Autran et al, 1997; Komanduri et al, 1998; Pontesilli
et al, 1999; Rinaldo et al, 1999; Wendland et al, 1999; Connick
et al, 2000). The development of new mycobacteria-speci®c T
cell lymphoproliferative responses has been correlated with
immune in¯ammatory reactions in patients with unusual clinical
manifestations of mycobacterial infections following the initi-
ation of HAART (Foudraine et al, 1999). In general, the
restoration of these responses has occurred rapidly, within the
®rst 3 mo of therapy.
T lymphocyte proliferative and DTH responses do not appear
to be unilaterally reconstituted in the setting of HAART.
Despite two reports of recovery of tetanus-speci®c lymphocyte
proliferative responses in small numbers of patients (Pontesilli
et al, 1999; Rinaldo et al, 1999), a much larger study did not
reveal reconstitution of tetanus-speci®c lymphocyte proliferative
responses after 1 y of HAART therapy (Connick et al, 2000).
The selective failure of tetanus responses to increase most likely
is due to the infrequency of exposure to tetanus compared with
Candida, CMV, MAC, and MTB, to which individuals are
likely re-exposed endogenously. Indeed, a tetanus booster
vaccination given to subjects after 1 y of HAART therapy,
resulted in reconstitution of tetanus-speci®c lymphocyte pro-
liferative responses (Valdez et al, 2000), suggesting that antigen-
speci®c precursors had not been completely eliminated in these
subjects, but only depleted. Similarly, in the ®rst year of this
same study Candida DTH responses were recovered after 12 wk
of therapy, whereas new mumps DTH responses did not appear
until tested for at week 48 (Connick et al, 2000). The early
recovery of Candida DTH responses was believed to be due to
endogenous re-exposure to this antigen. The later recovery of
mumps responses was believed to be due to reconstitution of
the booster phenomenon such that skin tests at week 12
boosted the numbers of mumps-speci®c cells so that these
responses became detectable at 48 wk. These ®ndings suggest
that HAART improves the immune system's ability to respond
to antigen on exposure, but that HAART does not reconstitute
pre-existing responses in the absence of re-exposure. Thus, the
rejuvenated immune system on HAART is not identical to the
one prior to HIV-1 infection.
2Valdez H, Connick E, Lederman M, et al: T-lymphocyte changes after
3 years of controlled viral replication. 8th Conference on Retroviruses and
Opportunistic Infections, Chicago, February 4±8, Alexandria, VA: Foundation
for Retrovirology and Human Health 2001 (abstr. 372)
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THE IMPACT OF HAART ON HIV-1-SPECIFIC IMMUNE
RESPONSES
It is not fully understood why most HIV-1-infected individuals are
unable to mount an immune response that is capable of controlling
and eradicating HIV-1 replication. A variety of mechanisms of
immune evasion have been described in HIV-1 infection, including
rapid selection of virus isolates that contain mutations within
cellular and humoral epitopes that confer resistance (Wrin et al,
1994; Nowak et al, 1995; Borrow et al, 1997; Goulder et al, 1997),
and downregulation of MHC class I molecules on virus-producing
cells (Collins et al, 1998). Loss of HIV-1-speci®c CD4+ T
lymphocyte proliferative responses, which usually occur quite
early in infection (Wahren et al, 1987; Berzofsky et al, 1988;
Krowka et al, 1989), has been hypothesized to be critical to the
immunopathogenesis of HIV-1 infection as well. The ®nding that
these responses are preserved in long-term nonprogressors
(Schwartz et al, 1994; Rosenberg et al, 1997), who have low levels
of virus replication, has been interpreted as evidence that HIV-1-
speci®c CD4+ T cell functions are essential for immunologic
control of the virus. A critical question is whether HAART may
reverse defects in HIV-1-speci®c immune responses, and thereby
enhance immunologic control in infected individuals.
Studies of HAART in chronically infected individuals have
shown that HIV-1-speci®c CD4+ lymphocyte proliferative
responses are rarely reconstituted (Autran et al, 1997; Plana et al,
1998; Pontesilli et al, 1999; Connick et al, 2000). Reconstitution of
these responses has been reported in some individuals in early stages
of disease (Al-Harthi et al, 2000). It has also been reported to occur
in individuals with transient interruptions of HAART (Haslett et al,
2000; Ruiz et al, 2000), suggesting that re-exposure to HIV-1
antigens may reconstitute these responses. HIV-1-speci®c CD4+ T
cells have been detected in untreated individuals using more
sensitive ¯ow cytometric studies of antigen-induced interferon-g
production (Pitcher et al, 1999). Long-term administration of
HAART to chronically infected individuals results in a decrease in
HIV-1-speci®c CD4+ lymphocytes detected by these ¯ow
cytometric assays (Pitcher et al, 1999).
Other HIV-1-speci®c immune responses appear to decline in the
setting of HAART as well, presumeably due to decreased antigen
concentration. HIV-1-speci®c CD8+ cytotoxic T lymphocyte
(CTL) memory and effector responses decline in chronically
infected individuals treated with HAART (Gray et al, 1999; Kalams
et al, 1999; Ogg et al, 1999). Humoral immune responses to HIV-1
also decline in chronically infected individuals treated with
HAART. HIV-1 gp120-speci®c antibody secreting cells rapidly
decline in number with the institution of HAART, and anti-gp120
titers fall more gradually (Morris et al, 1998).
Treatment of acute seroconverters with HAART appears to have
different immune consequences than treatment of chronically
infected individuals. Institution of HAART during or shortly after
seroconversion has been reported to result in preservation of HIV-
1-speci®c lymphocyte proliferative responses (Rosenberg et al,
2000). In addition, treatment of acute seroconverters has been
reported to result in strong HIV-1-speci®c neutralizing antibodies
(Barassi et al, 2000), which are distinctly unusual in chronic HIV-1
infection (Wrin et al, 1994). HIV-1-speci®c CTL responses in
seroconverters who receive HAART appear to be affected in the
same way as those in chronically infected individuals treated with
HAART, in that they decline in subjects with maximal virus
suppression, but are maintained or increase in those in whom viral
suppression is incomplete (Dalod et al, 1998; Markowitz et al,
1999).
Because virus-speci®c responses could potentially synergize with
HAART and enhance control of viral replication (Rosenberg and
Walker, 1998), a number of strategies are currently under
investigation to bolster HIV-1-speci®c CD4+ and CD8+ T cell
responses. Based on the observations that interruption of HAART
can result in augmentation of both CD4+ and CD8+ HIV-1-
speci®c responses, studies of the immunologic and virologic effects
of intermittent withdrawal of antiretroviral therapy have been
undertaken. Preliminary results suggest that interruption of treat-
ment in subjects treated during acute HIV-1 seroconversion may
result in enhanced virologic control (Rosenberg et al, 2000),
perhaps through preservation of HIV-1-speci®c CD4+ T cell
responses. Multiple interruptions in therapy have been suggested to
be important in augmenting virologic control, perhaps through
additional stimulation of HIV-1-speci®c cellular responses
(Rosenberg et al, 2000). Interruption of therapy in chronically
infected individuals, on the other hand, has not yielded much
evidence of enhanced virologic control thus far (Neuman et al,
1999; Ortiz et al, 1999; Ruiz et al, 2000). Further studies are needed
to determine if these strategies are safe or successful in inducing
HIV-1-speci®c immune responses, and if these immune responses
are associated with more effective elimination of virus or more
sustained viral suppression.
Therapeutic vaccination is another approach currently under
investigation to augment HIV-1-speci®c immunity in HAART-
treated individuals. SIV-infected macaques who were treated with
HAART 15 d after experimental infection and then subsequently
vaccinated, have demonstrated enhanced virologic control upon
discontinuation of antiretroviral therapy compared with animals
who received antiretroviral therapy alone (Hel et al, 2000). Similar
studies in humans are ongoing, but there are no de®nitive results to
date.
SUMMARY AND CONCLUSIONS
Immune reconstitution in the setting of potent combination
antiretroviral chemotherapy has resulted in remarkable decreases
in morbidity and mortality from HIV-1 infection over the past 5 y.
Both clinical and laboratory data suggest that HAART restores the
ability of the immune system to respond to antigens upon re-
exposure. Nevertheless, immune reconstitution is neither uniform
nor complete in all treated individuals. Some HIV-1-associated
malignancies have not declined in frequency, and the long-term
impact of HAART on these and other HIV-1-associated illnesses
remains to be determined. CD4+ T cell counts do not normalize in
all treated individuals and CD4+ T cell functional studies suggest
that many HIV-1-infected individuals treated with HAART
continue to have selected defects. The clinical implications of
subnormal CD4+ T cell numbers and incomplete immune restor-
ation are unknown.
Although HAART has revolutionized the treatment of HIV-1
infection, it is not the solution for this disease. A small fraction of
individuals are absolutely intolerant of the medications and
therefore unable to take them. Many others suffer side-effects,
but continue to use them with substantial impairments in their
quality of life (Lucas et al, 1999). As many as two-thirds of treated
individuals do not achieve or maintain complete virologic
suppression (Lucas et al, 1999). Although partial suppression of
virus has been shown to result in clinical bene®ts, ultimately
individuals with incomplete virologic suppression will develop
resistant viruses and then lose the immune bene®ts that they have
achieved with HAART. Transmission of resistant virus is increasing
(Little et al, 1999), and limits the medications that individuals
infected with resistant strains may receive. Lastly, the majority of
HIV-1-infected people in the world currently do not have access to
HAART, and therefore do not bene®t from it at all. A better
understanding of the immunopathogenesis of HIV-1 infection that
has been brought about by HAART may ultimately lead to better
therapies for this infection, and possibly decrease or eliminate the
need for antiretroviral drug therapy in the future.
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